CD19 and pancreatic neoplasm: The efficacy of CAR T cells was found to be limited in solid tumors, particularly in pancreatic cancer, as there is a lack of an ideal target analogous to CD19 (B cell activation receptor), as well as the immunosuppressive environment of pancreatic cancer [118].